To amend sections 1751.91, 3923.89, 4729.01, 5164.14, and 5167.051 and to enact sections 4729.392 and 4729.393 of the Revised Code to authorize pharmacists to screen, test, and provide treatment for certain respiratory health conditions.
SB230 would expand the scope of pharmacy practice in Ohio by authorizing pharmacists, under a statewide written protocol adopted by the State Board of Pharmacy, to screen patients, order and administer certain laboratory and diagnostic tests, evaluate results, and provide treatment for specified respiratory health conditions. The bill expressly covers influenza, group A streptococcal pharyngitis, COVID-19, respiratory syncytial virus (RSV), and other respiratory conditions that may be added by rule. It also allows pharmacists to initiate drug therapy as part of this authority and to delegate certain technical and administrative tasks to trained pharmacy personnel under direct supervision.
The bill also updates Ohio insurance and Medicaid payment statutes so that pharmacists can be reimbursed for covered health care services in the same manner as other providers when the service is one the pharmacist is authorized to perform. This includes changes to health insuring corporation coverage, sickness and accident insurance, public employee benefit plans, Medicaid, and the Medicaid care management system. The bill amends definitions in the pharmacy chapter to incorporate the new screening, testing, and treatment authority and makes the new reimbursement provisions applicable to certain contracts, policies, and plans issued or renewed on or after the effective date.
SB230 would materially expand pharmacists’ legal authority under Ohio law by adding a new section to Chapter 4729 that permits pharmacist-led screening, testing, evaluation, and treatment for selected respiratory illnesses. It would also require or allow payment/reimbursement for those pharmacist services under private insurance, public employee benefit plans, and Medicaid when the underlying benefit covers the service, thereby affecting insurers, Medicaid administrators, pharmacies, and patients seeking more accessible point-of-care treatment. The bill would likely require rulemaking by the State Board of Pharmacy to establish the statewide protocol and operational standards.
The available context shows no recorded committee testimony or votes, so there is no documented public debate to gauge support or opposition. Based on the bill’s structure, the measure appears designed to be a health-access and workforce-expansion bill, suggesting a generally pro-expansion posture toward pharmacist-delivered care. However, because no transcripts or vote history are provided, sentiment can only be characterized as neutral-to-supportive by the bill’s framing rather than by observed legislative action.
The main policy questions likely center on the scope of pharmacist authority, clinical oversight, and reimbursement obligations. Potential points of contention include whether pharmacists should be allowed to initiate drug therapy for respiratory conditions, how broad the board’s rulemaking authority should be for adding “other respiratory conditions,” and whether insurers and Medicaid should be required to reimburse pharmacists on the same basis as other providers. Stakeholders most likely to focus on these issues include pharmacists and pharmacy organizations, insurers, Medicaid administrators, physicians, and public health advocates concerned with access, quality, and cost.